This webinar discusses how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.

A viable cell therapy business model and reimbursement plan needs to begin ‘with the end in mind’, more so than in traditional small molecule development. Much higher upfront capital expenditure, the unique needs of diverse patient populations, and potential logistical and reimbursement challenges may be barriers that manufacturers face in launching novel, targeted therapies. In niche markets as well as broader therapeutic areas that cell and gene therapies are now targeting, getting the product to the patient both seamlessly and efficiently is crucial. So innovative approaches that incorporate the needs of specific patient populations, payers, and providers need to be explored during clinical development.

This innovation needs to occur across the entire spectrum, from the referral, evaluation and approval of therapy, right through to administration and monitoring. Some core principles will not change, such as reimbursement strategies will primarily be driven by payer type, site of care, coverage factors (e.g., level of unmet need, cost offsets, strength of clinical data, etc.) and product cost. However manufacturing is an area where new thinking, such as decentralized approaches to manufacturing, could increase the likelihood of viable cells being available to a greater number of patients. And this could potentially be a first step in democratizing the cost of expensive cell therapies to make them more accessible to patients from all socio-economic backgrounds.

Key Topics Include:

  • Understand challenges associated with commercializing cell therapies, recent advancements, and where the greatest barriers remain.
  • Gain a better understanding of who currently has access to cell and gene therapies.
  • Learn how manufacturers can promote equity and ensure access.


Senior Vice President
Real-World Evidence and HEOR Strategy
Magnolia Market Access

Pamela Landsman-Blumberg is an industry recognized subject matter expert in real world data (RWD) evaluation and real world evidence (RWE) generation. Her work product has improved the evidence- and value-based decision making of payers, providers, and policymakers. Pam currently advises industry and trade associations on all aspects of fit-for-purpose RWD, RWE, and HEOR strategy.

Senior Vice President
Reimbursement & Market Access
Magnolia Market Access

Amanda O’Hora is an industry leader in the areas of reimbursement (coding, coverage, and payment), manufacturer patient support services, health policy, and market access for payers, providers and patients. She is adept at integrating data analytics, market insights, and personal experience into developing strategies, putting them into action and enhancing them in response to market changes.

Senior Vice President
Commercialization Strategy
Magnolia Market Access

Ajay Keshava has over 20 years of experience both in industry and management consulting, in which he has covered all aspects of cross-functional development, approval and launch of drug, device and combination products, business development and acquisitions, interactions with regulators, as well as organizational design and scale up for both pharma and device companies.

Production Partner

Magnolia Market Access

Magnolia Market Access provides tailored strategies and insights to pharmaceutical companies, device manufacturers, and trade associations meeting their market access, HEOR, and healthcare policy needs. Our experts provide 360-degree perspectives and spotlight data to shape policy, communicate value, secure reimbursement, and drive patient access.

Additional Content From Magnolia Market Access

Related Content